Literatur
- 1
Diago M, Romero-Gomez M, Crespo J. et al .
Peginterferon alfa-2a (40 KD) (Pegasys®) and ribavirin (Copegus®) in patients infected
with HCV Genotype 1 who failed to respond to interferon-ribavirin: Final results of
the spanish high-dose induction pilot trial.
Hepatology.
2004;
40
389A
- 2
Herrine S K, Brown R S, Bernstein D E, Ondovik M S, Lentz E, Te H.
Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed
after or had a viral breakthrough on therapy with standard interferon alpha-2b plus
ribavirin: a pilot study of efficacy and safety.
Dig Dis Sci.
2005;
50
719-726
- 3
Jacobson I, Russo M W, Brown R S. et al .
Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C:
A trial in prior nonresponders to interferon monotherapy or combination therapy and
in combination therapy relapsers.
Hepatology.
2002;
36
358A
- 4
Kaiser S, Hass H, Gergor M.
Successfull retreatment of chronic hepatitis C patients with a nonresponse to standard
interferon/ribavirin using daily consensus interferon and ribavirin.
Hepatology.
2004;
40
240A
- 5
Teuber G, Kallinowski B, Niederau C. et al .
Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic
hepatitis C not responding to a previous antiviral treatment with standard interferon
and ribavirin.
Gastroenterology.
2003;
124
T1216
Dr. med. Nicolas Hoepffner
Medizinische Klinik I, J. W. Goethe Universitätsklinik
Theodor Stern Kai 7
60590 Frankfurt
Telefon: 069 6301 5333
Fax: 069 6301 6247
eMail: n.m.hoepffner@em.uni-frankfurt.de
